Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference
Clearside Biomedical, Inc. (Nasdaq: CLSD) will feature Chief Medical Officer Thomas A. Ciulla in a Fireside Chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) will feature Chief Medical Officer Thomas A. Ciulla in a Fireside Chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET in New York. This event emphasizes Clearside's innovative SCS injection platform, which enables non-surgical therapy delivery to the eye, targeting conditions that threaten vision. The live and archived webcast will be accessible via the Clearside website for three months. Clearside's first product, XIPERE, is an injectable suspension currently available in the U.S.
Details
News Market Reaction – CLSD
The recorded move for CLSD in the trading session of this news was +4.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., June 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.